WJCD  Vol.2 No.2 , April 2012
Single-centre all-comers registry reveals promising long-term clinical results of the EndeavorTM-Stent
ABSTRACT
Background: To evaluate the safety and efficacy of the EndeavorTM-Stent-Stent (Medtronic Corp., USA) in daily practice. Material and methods: Data come from a prospective single-centre registry. Between 2005 and 2007 all patients, who received at least one Endeavor? coronary stent, were included into a registry. Patients were contacted after 12 and 24 - 36 months. Results: 326 patients (97 females, mean age 67.5 ± 10.3 years) were included. From these patients 137 (42%) had a 3-vessel disease, 96 (29%) presented with myocardial infarction ≤ 72 hrs, 19 (6%) with a left ventricular ejection fraction < 25%. In summary, 379 lesions (50% type B2, 23% type C, mean lesion length 20.2 ± 10.0 mm, mean reference vessel diameter 3.0 ± 0.4 mm) were treated with EndeavorTM-Stent-Stents. Per patient, 0.4 ± 0.7 bare metal stents were implanted. Median follow-up time was 35.3 months, during follow-up 165 patients (50.6%) had repeated angiography. After 12 (24) months overall mortality was 5.8% (7.3%), cardiac mortality 3.1% (3.5%), myocardial infarction rate 1.5% (4.1%), target-vessel revascu-larization rate 8.7% (12.4%), target-lesion revascu-larization rate 6.1% (8.4%), and cumulative MACE-rate 14.1% (21.9%). In total, 2 definite or likely stent-thromboses (0.6%) occurred during follow-up. Logistic regression revealed the treatment of saphenous vein grafts and aorto-coronary ostial lesions as risk factors for target lesion revascularization. Conclusion: The EndeavorTM-Stent-Stent is a safe and effective drug-eluting stent in the treatment of daily-life coronary patients. Treatment of vein grafts and aorto-coronary ostial lesions appear to be associated with a higher need for re-interventions.

Cite this paper
Hertting, K. , Wieneke, A. , Hausmann, D. , Zeiler, C. , Pott, C. and Raut, W. (2012) Single-centre all-comers registry reveals promising long-term clinical results of the EndeavorTM-Stent. World Journal of Cardiovascular Diseases, 2, 82-89. doi: 10.4236/wjcd.2012.22013.
References
[1]   Fajadet, J., Wijns, W., Laarman, G.J., et al. (2010) Long-Term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: Five year outcomes in the ENDEAVOR II study. EuroIntervention, 6, 562-567.

[2]   Meredith, I.T., Ormiston, J., Whitbourn, R., et al. (2009) Five-Year clinical follow-up after implantation of the Endeavor zotarolimus-eluting: ENDEAVOR I, first-in-human study. Catherization and Cardiovascular Interventions, 74, 989-995. doi:10.1002/ccd.22206

[3]   Ryan, T.J., Faxon, D.P., Gunnar, R.M., et al. (1988) Guidelines for percutaneous transluminal coronary an- gioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). Circulation, 78, 486-502. doi:10.1161/01.CIR.78.2.486

[4]   Mancia, G., De Backer, G., Dominiczak, A., et al. (2007) Guidelines for the management of arterial hypertension. European Heart Journal, 28, 1462-1536. doi:10.1093/eurheartj/ehm236

[5]   Rydén, L., Standl, E., Bartnik, M., et al. (2007) Guidelines on diabetes, prediabetes, and cardiovascular diseases: Executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 28, 88-136.doi:10.1093/eurheartj/ehl260

[6]   Van de Werf, F., Bax, J., Betriu, A., et al. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. European Heart Journal, 29, 2909-2945. doi:10.1093/eurheartj/ehn416

[7]   Bassand, J.P., Hamm, C.W., Ardissino, D., et al. (2007) Guidelines for the diagnosis and treatment of non-ST- segment elevation acute coronary syndromes. European Heart Journal, 28, 1598-1660. doi:10.1093/eurheartj/ehm161

[8]   Hochman, J.S., Sleeper, L.A., White, H.D., et al. (2001) One-year survival following early revascularization for cardiogenic shock. Journal of the American Medical As- sociation, 285, 190-192. doi:10.1001/jama.285.2.190

[9]   Levey, A.S., Coresh, J., Balk, E., et al. (2003) National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Annals of Internal Medicine, 139, 137-147.

[10]   Biondi-Zoccai, G.G., Agostoni, P., Sangiorgi, G.M., et al. (2006) Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. European Heart Journal, 27, 540-546. doi:10.1093/eurheartj/ehi618

[11]   Cutlip, D.E., Windecker, S., Mehran, R., et al. (2007) Clinical end points in coronary stent trials: A case for standardized definitions. Circulation, 115, 2344-2351. doi:10.1161/CIRCULATIONAHA.106.685313

[12]   Kandzari, D.E., Mauri, L., Popma, J.J., et al. (2011) Late-Term clinical outcomes with zotarolimus- and si- rolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (a randomized controlled trial of the medtronic endeavor drug [ABT-578] eluting coronary stent system versus the cypher sirolimus-eluting coronary stent system in de novo native coronary artery lesions). Journal of the American College of Cardiology Cardiovascular Interventions, 4, 543-550.

[13]   Leon, M.B., Nikolsky, E., Cutlip, D.E., et al. (2010) Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease) trial. Journal of the American College of Cardiology Cardiovascular Interventions, 3, 1043-1050.

[14]   Lotan, C., Meredith, I.T., Mauri, L., et al. (2009) Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry. Journal of the American College of Cardiology Cardiovascular Interventions, 2, 1227-1235.

[15]   Meredith, I., Rothman, M., Erglis, A., et al. (2011) Ex- tended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: Two-Year follow-up from the E-five registry. Catherization and Cardiovascular Interventions, 77, 993- 1000. doi:10.1002/ccd.22803

[16]   Mukherjee, D., Moliterno, D.J. (2009) Second-Generation drug-eluting stents and the continuous need for rapidly available real-world data. Journal of the American College of Cardiology Cardiovascular Interventions, 2, 1236-1239.

[17]   Ligthart, S., Vlemmix, F., Dendukuri, N., Brophy, J.M. (2007) The cost-effectiveness of drug-eluting stents: A systematic review. Canadian Medical Association Journal, 176, 199-205. doi:10.1503/cmaj.061020

[18]   Wijns, W., Kolh, P., Danchin, N., et al. (2010) Guidelines on myocardial revascularization. European Heart Journal, 31, 2501-2555.

[19]   Steinberg D.H., Mishra S., Javaid A., et al. (2007) Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (≥3.5 mm) coronary arteries. American Journal of Cardiology, 99, 599-602. doi:10.1016/j.amjcard.2006.09.105

[20]   Yan, B.P., Ajani, A.E., New, G., et al. (2008) Are drug-eluting stents indicated in large coronary arteries? Insights from a multi-centre percutaneous coronary interention registry. International Journal of Cardiology, 130, 374-379. doi:10.1016/j.ijcard.2008.06.046

[21]   Lasala, J.M., Cox, D.A., Lewis, S.J., et al. (2009) Expanded use of the TAXUS Express stent: two year safety insights from the 7500 patients ARRIVE Registry program. EuroIntervention, 5, 67-77.

[22]   Urban, P., Gershlick, A.H., Guaglium,i G., et al. (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice. One-year follow-up of the e-Cypher registry. Circulation, 113, 1434-1441. doi:10.1161/CIRCULATIONAHA.104.532242

[23]   Rasmussen, K., Maeng, M., Kaltoft, A., et al. (2010) Effi- cacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomized controlled superiority trial. Lancet, 375, 1090-1099. doi:10.1016/S0140-6736(10)60208-5

[24]   Mauri, L., Massaro, J.M., Jiang, S., et al. (2010) Long- Term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents. Journal of the American College of Cardiology Cardiovascular Interventions, 3, 1240- 1249.

[25]   Kang, W.C., Ahn, T., Lee, K., et al. (2011) Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction. EuroIntervention, 7, 936-943.

[26]   Zahn, R., Hamm, C.W., Schneider, S., et al. (2005) Inci- dence and predictors of target vessel revascularization and the clinical event rates of the sirolimus-eluting coro- nary stent (results from the proscective multicenter German cypher stent registry). American Journal of Cardi- ology, 95, 1302-1308. doi:10.1016/j.amjcard.2005.01.072

[27]   Iakovou, I., Ge, L., Michev, I., et al. (2004) Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. Journal of the American College of Cardiology, 44, 967-971. doi:10.1016/j.jacc.2004.05.058

[28]   Luz, A., Hughes, C., Magalh?es, R., et al. (2011) Stent implantation in aorto-ostial lesions: Long-Term follow-up and predictors of outcome. EuroIntervention, 7, 1069- 1076.

[29]   Nakatani, D., Ako, J., Tremmel, J.A., et al. (2011) Sex differences in neointimal hyperplasia following endeavor zotarolimus-eluting stent implantation. American Journal of Cardiology, 108, 912-917. doi:10.1016/j.amjcard.2011.05.019

[30]   Byrne, R.A., Kastrati, A., Tiroch, K., et al. (2010) 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug eluting stents. Journal of the American College of Cardiology, 55, 2536- 2543. doi:10.1016/j.jacc.2010.03.020

[31]   Wenaweser, P., Daemen, J., Zwahlen, M., et al. (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2- institutional cohort study. Journal of the American Col- lege of Cardiology, 52, 1134-1140. doi:10.1016/j.jacc.2008.07.006

[32]   Fan, C., Kim, J.S., Lee, J.M., et al. (2010) Different vas- cular healing patterns with various drug-eluting stents in primary percutaneous coronary interventions for ST- segment elevation myocardial infarction: optical coherence tomographic findings. American Journal of Cardiology, 105, 972-976. doi:10.1016/j.amjcard.2009.11.018

[33]   Kim, J.S., Jang, I.K., Fan, C., et al. (2009) Evaluation in 3 months duration of neointimal coverage after zo- tarolimus-eluting stent implantation by optical coherence tomography: The ENDEAVOR OCT trial. Journal of the American College of Cardiology Cardiovascular Inter- ventions, 2, 1240-1247.

[34]   Li, S., Wang, Y., Gai, L., et al. (2011) Evaluation of neoin-timal coverage and apposition with various drug-eluting stents over 12 months after implantation by optical coherence tomography. International Journal of Cardiology. doi:10.1016/j.ijcard.2011.05.076

[35]   Hahn, J.Y., Song, Y.B., Choi, J.H., et al. (2010) Three-month dual antiplatelet therapy after implantation of zo- tarolimus-eluting stents: The DATE (duration of dual antiplatelet therapy after implantation of endeavor stent) registry. Circulation Journal, 74, 2314-2321. doi:10.1253/circj.CJ-10-0347

 
 
Top